Low Serum Dehydroepiandrosterone Is Associated With Diabetic Kidney Disease in Men With Type 2 Diabetes Mellitus

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Jul 5

PMID 35784547

Authors

Xinxin Zhang

Jinfeng Xiao

Xin Li

Jingqiu Cui

Kunling Wang

Qing He

Ming Liu

Affiliations

Soon will be listed here.

Abstract

Background: The associations of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) with diabetic kidney disease (DKD) remained unclear. Thus, this cross-sectional study aimed to explore the associations of DHEA and DHEAS with the risk of DKD in patients with T2DM.

Methods: The information of 1251 patients with T2DM were included in this study. Serum DHEA and DHEAS were quantified using liquid chromatography-tandem mass spectrometry assays. Multivariate logistic regression analyses were used to assess the associations of DHEA and DHEAS with DKD as well as high urine albumin to creatinine ratio (ACR).

Results: In men with T2DM, the risk of DKD decreased with an increasing DHEA concentration after adjustment for traditional risk factors; the fully adjusted OR (95% CI) for tertile3 vs tertile1 was 0.37 (0.19-0.70; P = 0.010 for trend). Similarly, when taking high ACR as the outcome, low DHEA levels were still significantly associated with increased odds of high ACR (OR, 0.37; 95% CI, 0.19-0.72 for tertile3 vs tertile1; P = 0.012 for trend). The restricted cubic spline showed that the risk of DKD gradually decreased with the increment of serum DHEA levels (P-overall = 0.007; P-nonlinear = 0.161). DHEAS was not independently associated with the risk of DKD in men. In contrast, no significant relationships were found between DHEA and DHEAS and the risk of DKD in women (all P > 0.05).

Conclusions: In men with T2DM, low serum DHEA levels were independently related to the risk of DKD after adjustment for traditional risk factors. Our finding highlights the potential role of DHEA in the development of DKD in men with T2DM.

Citing Articles

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers.

Rentflejsz J, Wojszel Z J Clin Med. 2024; 13(4).

PMID: 38398421 PMC: 10889814. DOI: 10.3390/jcm13041107.

Low serum dehydroepiandrosterone levels are associated with diabetic retinopathy in patients with type 2 diabetes mellitus.

Zhang X, Huang Y, Xu N, Feng W, Qiao J, Liu M J Diabetes Investig. 2023; 14(5):675-685.

PMID: 36811237 PMC: 10119925. DOI: 10.1111/jdi.13997.

References

Weiss E, Villareal D, Fontana L, Han D, Holloszy J . Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011; 3(5):533-42. PMC: 3156603. DOI: 10.18632/aging.100327. View

Fukui M, Kitagawa Y, Kamiuchi K, Hasegawa G, Yoshikawa T, Nakamura N . Low serum dehydroepiandrosterone sulfate concentration is a predictor for deterioration of urinary albumin excretion in male patients with type 2 diabetes. Diabetes Res Clin Pract. 2006; 73(1):47-50. DOI: 10.1016/j.diabres.2005.11.006. View

Aribas E, Ahmadizar F, Mutlu U, Ikram M, Bos D, Laven J . Sex steroids and markers of micro- and macrovascular damage among women and men from the general population. Eur J Prev Cardiol. 2021; 29(9):1322-1330. DOI: 10.1093/eurjpc/zwaa031. View

Brignardello E, Gallo M, Aragno M, Manti R, Tamagno E, Danni O . Dehydroepiandrosterone prevents lipid peroxidation and cell growth inhibition induced by high glucose concentration in cultured rat mesangial cells. J Endocrinol. 2000; 166(2):401-6. DOI: 10.1677/joe.0.1660401. View

Tuttle K, Bakris G, Bilous R, Chiang J, de Boer I, Goldstein-Fuchs J . Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37(10):2864-83. PMC: 4170131. DOI: 10.2337/dc14-1296. View

Alicic R, Rooney M, Tuttle K . Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017; 12(12):2032-2045. PMC: 5718284. DOI: 10.2215/CJN.11491116. View

Dhatariya K, Bigelow M, Nair K . Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005; 54(3):765-9. DOI: 10.2337/diabetes.54.3.765. View

Rice S, Agarwal N, Bolusani H, Newcombe R, Scanlon M, Ludgate M . Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab. 2009; 94(6):1966-72. DOI: 10.1210/jc.2008-2636. View

Kiersztan A, Gaanga K, Witecka A, Jagielski A . DHEA-pretreatment attenuates oxidative stress in kidney-cortex and liver of diabetic rabbits and delays development of the disease. Biochimie. 2021; 185:135-145. DOI: 10.1016/j.biochi.2021.03.010. View

10.

Hsu H, Yen C, Chen C, Hsu K, Hsiao C, Lee C . Low plasma DHEA-S increases mortality risk among male hemodialysis patients. Exp Gerontol. 2012; 47(12):950-7. DOI: 10.1016/j.exger.2012.08.012. View

11.

Tivesten A, Vandenput L, Carlzon D, Nilsson M, Karlsson M, Ljunggren O . Dehydroepiandrosterone and its sulfate predict the 5-year risk of coronary heart disease events in elderly men. J Am Coll Cardiol. 2014; 64(17):1801-10. DOI: 10.1016/j.jacc.2014.05.076. View

12.

Callies F, Fassnacht M, van Vlijmen J, KOEHLER I, Huebler D, Seibel M . Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab. 2001; 86(5):1968-72. DOI: 10.1210/jcem.86.5.7483. View

13.

Wan H, Zhang K, Wang Y, Chen Y, Zhang W, Xia F . The Associations Between Gonadal Hormones and Serum Uric Acid Levels in Men and Postmenopausal Women With Diabetes. Front Endocrinol (Lausanne). 2020; 11:55. PMC: 7044188. DOI: 10.3389/fendo.2020.00055. View

14.

Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R . Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014; 74(11):1195-207. DOI: 10.1007/s40265-014-0259-8. View

15.

Fukui M, Ose H, Nakayama I, Hosoda H, Asano M, Kadono M . Association between urinary albumin excretion and serum dehydroepiandrosterone sulfate concentrations in women with type 2 diabetes. Diabetes Care. 2007; 30(7):1886-8. DOI: 10.2337/dc06-2325. View

16.

Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson K . Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation. 2009; 120(13):1231-40. DOI: 10.1161/CIRCULATIONAHA.109.848911. View

17.

Wang C, Zhang W, Wang Y, Wan H, Chen Y, Xia F . Novel associations between sex hormones and diabetic vascular complications in men and postmenopausal women: a cross-sectional study. Cardiovasc Diabetol. 2019; 18(1):97. PMC: 6668151. DOI: 10.1186/s12933-019-0901-6. View

18.

Perez de Heredia F, Larque E, Zamora S, Garaulet M . Dehydroepiandrosterone modifies rat fatty acid composition of serum and different adipose tissue depots and lowers serum insulin levels. J Endocrinol. 2009; 201(1):67-74. DOI: 10.1677/JOE-08-0432. View

19.

Jesic M, Jesic M, Sajic S, Bogicevic D, Buljugic S, Maglajlic S . The effect of metabolic and hormonal parameters on microalbuminuria in adolescents with type 1 diabetes mellitus. Srp Arh Celok Lek. 2013; 141(5-6):315-9. DOI: 10.2298/sarh1306315j. View

20.

Jesse R, Loesser K, Eich D, Qian Y, Hess M, Nestler J . Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann N Y Acad Sci. 1995; 774:281-90. DOI: 10.1111/j.1749-6632.1995.tb17388.x-i1. View